Warning: strtotime(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 58

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 200

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 200

Nymox [NASDAQ:NYMX] reports safety data for NX-1207

User Rating: / 0
PoorBest 

Companies - Biotechnology Companies

Written by Hugh McManus

Warning: mktime(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 119 Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 247 Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 251 Warning: strftime(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /hermes/bosnacweb08/bosnacweb08az/b29/ipw.wellbeyo/public_html/libraries/joomla/utilities/date.php on line 252 Monday, 10 May 2010 17:52

Nymox reported good safety data for its lead drug, NX-1207, which is about to enter Phase III. The lead drug, NX-1207, targets benign prostatic hyperplasia—an enlarged prostate—a common ailment in older males.  The company has successfully completed trials in phase I and II; today, it reported, that on safety data as preparations are underway for the investigational drug to enter phase III clinical trials.  The company reported no significant safety concerns for the program.  Patient recruitment for two trials continues. The first trial is designated as NX02-0017 www.clinicaltrials.gov/ct2/show/NCT00918983?term=nymox&rank=1 The first trial has a tentative end date of August 2011.  The control group will take a placebo administered intravenously.  The experimental group will take a single intraprostatic injection of 2.5 mg NX-1207.  The company hopes to recruit 500 patients. The second trial is designated as NX02-0018 www.clinicaltrials.gov/ct2/show/NCT00945490?term=nymox&rank=2 where recruiting started about six weeks later from the first appears to be a duplicate effort.  The FDA requires two, successful (that is, meets the endpoint) clinical trials before approving a drug. Nymox is thinly traded, but may be worth considering as an investment closer to the conclusion of the current phase III trials. < Prev   Next >